AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|

27.5 C

New York

Thursday, September 10, 2026

/C O R R E C T I O N — Partillion Bioscience/

Holdun Family Office (Bahamas) Limited Confirms the Conclusion of its Licensed Wealth Management Business

Drivvr AI Welcomes Automotive Marketing Veteran Brian Voss as National Sales Director

Tag: presentation

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx¹.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

Latin Star Soleil & Vivalivetv Join the Kingdom of Kush 32nd Anniversary Gala: A Historic Night of Unity and Culture

The Kingdom of Kush Celebrates 32 Years of Rebirth, Sovereignty & Global Vision NEW YORK, June 13, 2025 /CNW/ -- On Friday, June 13, 2025, the...

WRJ Design Wins National Attention for Jackson Hole Home as “Ode to Art and Beauty”

LUXE honors design team with cover story featuring project inspired by the majestic Teton landscape, iconic modern architecture and a stunning blue-chip art collection JACKSON...

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2025

Aggregated presentation by day and by market

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

TCL Solar Showcases Next-Gen BC Modules at SNEC, Writing the Future of Solar Innovation with Technological Advancements

SHANGHAI, June 13, 2025 /PRNewswire/ -- From June 11th to 13th, the 18th International Solar Photovoltaic and Smart Energy Conference & Exhibition (SNEC PV+ 2025) was...

Newfoundland and Labrador Police Officers Presented with MADD Canada’s Team Nick Coates Awards for Outstanding Road Safety Efforts

ST. JOHN'S, Newfoundland and Labrador, June 13, 2025 (GLOBE NEWSWIRE) -- Police officers across Newfoundland and Labrador will be recognized at MADD Canada’s seventh annual Team Nick Coates Awards ceremony for their outstanding efforts to remove impaired drivers from the province’s roadways, waterways, and trails.

SMCP 2025 June Shareholders meeting

Press release - Paris, June 12^th, 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsPresentation